文献速递系统性红斑狼疮

贝利尤单抗在系统性红斑狼疮患者维持治疗中的疗效与安全性

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本回顾性观察研究纳入接受维持治疗的系统性红斑狼疮患者,比较羟氯喹或霉酚酸酯标准治疗组(n=103)与贝利尤单抗联合标准治疗组(n=100),采用倾向性评分逆概率加权减少选择偏倚。贝利尤单抗联合标准治疗组52周时糖皮质激素剂量和复发率显著低于标准治疗组,且52周内糖皮质激素减至0毫克的患者比例显著更高。

要点

  • 贝利尤单抗联合标准治疗组52周时糖皮质激素剂量和复发率显著低于标准治疗组。
  • 贝利尤单抗联合标准治疗组52周内糖皮质激素减至0毫克的患者比例显著高于标准治疗组。
  • 贝利尤单抗联合标准治疗组中,基线SELENA-SLEDAI评分低和基线糖皮质激素剂量低与糖皮质激素减停相关。

核心结论

  • 本研究提示贝利尤单抗适用于接受维持治疗的系统性红斑狼疮患者。

研究设计与样本

  • 本回顾性观察研究纳入接受维持治疗的系统性红斑狼疮患者,维持治疗定义为泼尼松等效剂量≤0.2毫克/公斤/天且SELENA-SLEDAI评分<10。
  • 标准治疗组为接受羟氯喹或霉酚酸酯的患者(n=103),贝利尤单抗联合标准治疗组为接受贝利尤单抗联合标准治疗的患者(n=100)。
  • 采用基于倾向性评分的逆概率治疗加权最小化选择偏倚,采用增长混合模型建模糖皮质激素剂量轨迹,主要终点为52周时糖皮质激素剂量。

主要发现

  • 逆概率治疗加权调整后两组患者特征无显著差异。
  • 贝利尤单抗联合标准治疗组糖皮质激素剂量显著下降。
  • 贝利尤单抗联合标准治疗组52周时糖皮质激素剂量和复发率显著低于标准治疗组。
  • 增长混合模型定义的52周内糖皮质激素减至0毫克的糖皮质激素减停组患者比例,贝利尤单抗联合标准治疗组显著高于标准治疗组。
  • 贝利尤单抗联合标准治疗组中,基线SELENA-SLEDAI评分低和基线糖皮质激素剂量低与糖皮质激素减停相关。

关键数值与推荐

  • 维持治疗定义为泼尼松等效剂量≤0.2毫克/公斤/天且SELENA-SLEDAI评分<10。
  • 标准治疗组为羟氯喹或霉酚酸酯治疗(n=103),贝利尤单抗联合标准治疗组为贝利尤单抗联合标准治疗(n=100)。
  • 主要终点为52周时糖皮质激素剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The efficacy of belimumab (BEL) during maintenance therapy in patients with SLE remains unclear in the real-life clinical setting. This study investigated the efficacy and safety of BEL in patients with SLE during maintenance therapy. METHODS: In this retrospective observational study, maintenance therapy was defined as low-dose glucocorticoid (GC) therapy (prednisolone equivalent dose of ≤0.2 mg/kg/day) in patients with a Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score <10. Participants comprised patients with SLE on HCQ or MMF [standard-of-care (SoC) group: n = 103] and those on BEL plus SoC (BEL+SoC group: n = 100). Selection bias was minimized using propensity score-based inverse probability of treatment weighting (IPTW). GC dose trajectories were modelled using growth mixture modelling (GMM). The primary end point was GC dose at 52 weeks. RESULTS: No significant difference was observed in patient characteristics between the two groups after IPTW adjustment. The BEL+SoC group exhibited a significant decrease in GC dose. GC dose at 52 weeks and relapse rate were significantly lower in the BEL+SoC group than in the SoC group. The proportion of patients in one of four groups defined by GMM for which GC dose was tapered to 0 mg within 52 weeks (GC tapering-discontinuation group) was significantly higher in the BEL+SoC group than in the SoC group. In the BEL+SoC group, low SELENA-SLEDAI score and low GC dose at baseline were associated with being GC dose-tapering discontinuation. CONCLUSION: The present study suggests that BEL is suitable for patients with SLE during maintenance therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Miyazaki Y, Nakayamada S, Sonomoto K, et al. Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022. PMID: 34962998. doi:10.1093/rheumatology/keab953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。